We are a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy. On June 1, 2015, we announced that our Board of Directors had approved a strategic plan pursuant to which we would immediately commence a process to seek an acquisition or partnership. Our lead assets target Sarco/endoplasmic reticulum Ca2+ -ATPase, or SERCA, enzymes, which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, which is a clinical syndrome characterized by poor heart function, resulting in inadequate blood flow to meet the body’s metabolic needs, as well as diabetes and neurodegenerative diseases. MYDICAR, our lead asset, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with heart failure. On April 26, 2015, we announced that the Phase 2b clinical trial of MYDICAR did not meet its primary or secondary endpoints.